| ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis |
96 |
| Recommendations for cognitive screening and management in multiple sclerosis care |
42 |
| Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study |
41 |
| Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod |
37 |
| Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis |
32 |
| Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment |
25 |
| Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis |
25 |
| High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial |
20 |
| Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study |
20 |
| Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial |
18 |
| Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions |
18 |
| Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis |
18 |
| e-Health and multiple sclerosis: An update |
18 |
| Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry |
17 |
| Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study |
17 |
| Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies |
17 |
| Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis |
17 |
| Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients |
16 |
| Animal models of multiple sclerosis: From rodents to zebrafish |
15 |
| Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities |
15 |
| Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor |
15 |
| Investigation of probiotics in multiple sclerosis |
14 |
| Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates |
14 |
| Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis? |
14 |
| Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations |
13 |
| Effects of an individual 12-week community-located start-to-run program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis |
13 |
| Predicting risk of secondary progression in multiple sclerosis: A nomogram |
13 |
| Five years before multiple sclerosis onset: Phenotyping the prodrome |
12 |
| Multiple sclerosis genetics |
12 |
| Neurofilaments and 10-year follow-up in multiple sclerosis |
12 |
| The role of infections in multiple sclerosis |
12 |
| Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis |
12 |
| Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization |
12 |
| Cytokine signaling in multiple sclerosis: Lost in translation |
11 |
| Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis |
11 |
| Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis |
11 |
| Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis |
11 |
| Preferential spinal cord volume loss in primary progressive multiple sclerosis |
11 |
| Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity |
11 |
| Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7T imaging |
10 |
| Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression |
10 |
| The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis |
10 |
| The Multiple Sclerosis Care Unit |
10 |
| Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review |
10 |
| Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study |
10 |
| Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study |
10 |
| Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients |
10 |
| Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study |
10 |
| Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis |
10 |
| Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis |
9 |
